Mobile health can help healthcare providers to improve the efficiency and cost effectiveness of the care they provide. Healthcare and ICT companies can also benefit from the increased sales opportunities resulting from the crossover of technologies.

Worldwide societal, technological, and economic changes are affecting the way people live and look after their health. New, more efficient and cost effective ways of delivering healthcare are needed. mHealth and telemedicine offer a solution to this problem. The growth potential of the mHealth and telemedicine market is only now becoming apparent as more healthcare and ICT vendors take part.

Scope of this research

• Identify current trends in healthcare, IT, and mobile technologies and adapt R&D and marketing efforts accordingly.
• Review the various initiatives that will impact private and public healthcare expenditure and affect ICT and healthcare companies’ sales.
• Assess the opportunities created by the integration of healthcare and mobile technologies to identify and exploit new growth channels.
• Anticipate the threats posed by the shift in healthcare provision and devise suitable strategies to maintain sales and market shares.

Research and analysis highlights

Demographic changes such as population ageing, health conditions linked to increased sedentariness and harmful lifestyle choices are key drivers of mobile health. Economic and financial pressures lead healthcare providers and governments to deliver more cost-effective healthcare through mobile health and telemedicine.

The pervasiveness of mobile cellular technology and the technological advances in IT, mobile telephony, and user equipment are creating the perfect environment for the remote provision of healthcare. The increased prevalence of chronic diseases is creating a market for telemonitoring equipment and services.

Developing countries stand to benefit the most from mobile health and telemedicine due to the greater lack of fixed ICT infrastructures and healthcare provision.

Key reasons to purchase this research

• What are the main drivers behind mobile health?
• How is mobile health affecting healthcare provision and health practices?
• Is mobile health the latest fad or is it a long-lasting trend?
• Is mobile health a global or localised phenomenon and how is it applied in various parts of the world?
• Who will benefit from the shift to mobile health and what are the best ways to exploit the new opportunities?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/12963/Trends-in-mHealth-and-Telemedicine.html

Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a “tipping point”, after which no medical industry players will want to be left behind.

This report covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, and medical devices. Each company profiled has at least one project in preclinical or Phase I study. Many also have later stage or launched products, which are covered briefly to illustrate the potential of the next generation of candidates.

Scope of this research

• Understand the concepts behind regenerative medicine, its potential applications, and advantages over traditional medicine.
• Compare the opportunities and challenges presented by the different therapeutic modalities.
• Understand the hurdles that must be overcome by regenerative medicine candidates before they can successfully enter the market.
• Identify emerging technologies that will shape the regenerative medicine industry in the coming years.
• Identify companies that may be competitors for a market, or alternatively potential partners or investment opportunities.

Research and analysis highlights

The first regenerative cell therapies to generate significant market value (within the next five years) will be based on allogeneic adult cells, and will target tissues that are naturally sheltered from patients’ immune systems.

Autologous cells are not rejected by the patient’s immune system, so are potentially safer than allogeneic cells and more suitable for permanent tissue replacement. “High tech” therapies based on reprogrammed autologous cells (e.g. induced pluripotent stem cells) may still be 20 years from market.

Tissue engineering still faces technical hurdles, including vascularization of grafted tissue and safe breakdown of scaffold materials. Research and regulatory efforts must be coordinated internationally to develop a stronger “evidence base” for regenerative medicine that is accessible and acceptable to all stakeholders.

Key reasons to purchase this research

• What is regenerative medicine and why are so many companies and investors excited about it?
• Which companies are currently developing new regenerative treatments and what approaches are they pursuing?
• What partnerships have been formed to develop new therapies, and where are the opportunities for further deals?
• What will the next generation of regenerative medicine candidates look like, and which indications will they treat?
• What hurdles do these candidates face en route to the marketplace?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/12964/Future-Directions-in-Regenerative-Medicine.html

The global ultrasound market has reached saturation. However, innovations in organ-specific imaging and the introduction of elastography features for cancer detection are creating niche markets for ultrasound.

This report examines the increasing adoption of ultrasound in both primary and secondary diagnosis. Manufacturers of ultrasound are introducing advanced equipment and probes for organ-specific imaging. Developments in elastography ultrasound over the past three years have provided new methods of cancer detection. Therapeutic uses of ultrasound are also covered.

Scope of this research

• Identify the market potential of the ultrasound market and the various ultrasound segments.
• Gain a quick and comprehensive understanding of the new innovations in ultrasound.
• Develop a framework for decision making by identifying the new advances that will shape the future of the ultrasound market.
• Benchmark performance against the leading ultrasound companies in terms of revenue growth and product launch capabilities.
• Learn from the business strategies of prominent ultrasound companies to target future growth markets effectively.

Research and analysis highlights

Regulatory entities have been imposing stringent regulations on imaging equipment manufacturers to lower the patient’s exposure to unwanted radiation, and this is favouring the use of ultrasound. There has also been an increase in the use of ultrasound owing to demographic effects and enhanced healthcare initiatives.

Ultrasound is not limited only to basic screening, but rather it is increasingly also being used for cancer detection and therapeutic purposes. Furthermore, developments such as 3D/4D imaging, elastography, and innovations in probe design have stimulated ultrasound sales in the last five years.

The emerging economies of Brazil, Russia, India, and China are for the first time investing in high-end product purchases owing to restructured government healthcare initiatives and the construction of new hospital facilities.

Key reasons to purchase this research

• Which will be the largest growth opportunities in the ultrasound market?
• What are the key drivers and resistors that will effect the growth of the ultrasound market?
• What are the new advances in ultrasound and which of the advances offer significant potential in the future?
• How have the leading companies built strong positions in the various segments of the ultrasound market?
• What is the trend in terms of new product launches in the various ultrasound segments?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/16206/The-Ultrasound-Market-Outlook-to-2016.html

From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama’s leading diagnostic analyst, Shara Rosen.

Far more than any other market research report, this report provides the most current and accurate picture of what is truly going on in molecular diagnostics in the United States.

Quantitative Data

Analyzed by the best-selling author of The Worldwide Market for In Vitro Diagnostics, now in its sixth edition, this new report includes surveys of molecular diagnostics focusing on these tests:

• Chlamydia and Gonorrhea
• HBV Viral Load
• HCV Viral Load, HCV Genotyping
• HIV Viral Load, HIV Genotyping
• HPV, HPV Genotyping
• Hospital Acquired Infections – MRSA, VRE
• Coagulation Factors – Factor II, Factor V Leiden
• Herpes Simplex Virus (HSV)
• Oncology Tests – BCR/ABL, Bladder Cancer, Her2Neu, MTHFR
• Transplant Medicine – HLA Typing
• Hereditary Disorders – Cystic Fibrosis (CF), Fragile X
• Respiratory Infections – Influenza A/B, Group A Strep, MTB (Tuberculosis), Bordetella pertussis, Adenovirus, Respiratory Virus
• Communicable Diseases – CMV (Cytomegalovirus), EBV (Epstein-Barr Virus), Group B Strep, Enterovirus

What Labs Do Now, What They are Planning in the Future

There has been much analysis in recent years about the inroads that DNA testing has made. This unique resource offers a way to measure that progress, and test assumptions aobut the evolution of DNA testing, critical information to adjust business stratetgies. This report looks at the following topics:

• What type of reagents are labs using (Commercial, ASR, Homebrew)
• Where tests are performed (Central/Core Testing Lab, Chemistry Lab, Cytology Lab, Genetics Lab, Hematology Lab, Microbiology Lab, Molecular Lab, Pathology Lab, Serology/Immunology Lab, Virology Lab)
• What Vendors are Labs Using
• What are there Purchasing Plans
• What Tests Do They Want in the Future
• Do They Outsource and at what Rate?
• Do They plan Vendor Changes?

A Representative Sample of the US Hospital Lab Industry

Emmes Group reached an extensive sample group – interviewing 14% of US hospital labs, 14% of public labs and 8% of US reference lab, where Emmes respondent numbers are compared to the Americian Hospital Directory. Such an undertaking would cost an individual company tens of thousands of dollars. This information is available to purchasers of this report at a fraction of the cost.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1631/Who-s-Doing-What-in-Molecular-Diagnostics-Kalorama-Emmes-Survey-of-US-Laboratories.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine.

From Emerging to Emergent Technology

Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. At each step of the way, Kalorama Information has reported on its progress, and in this latest market research report we look at the present state of the market, and the advances that have made DNA testing routine.

Many molecular tests are CE Marked and FDA-cleared and many more are in development. The result is that molecular testing is indicated in many areas of health care.

Molecular Testing Compiled and Analyzed and Explained by a Leading Expert

Authored by lead Kalorama diagnostic analyst Shara Rosen, Kalorama Information’s World Market for Molecular Diagnostics is the most comprehensive global market report available on the emergent field of molecular diagnostics.

This report covers key platforms of molecular diagnostics, including the following :

• Polymerase Chain Reaction (PCR)
• Non-PCR Amplification Technologies, including:
  • bDNA
  • TMA
  • SDA
  • LIPA
  • NASBA
  • Invader
  • Others
• In-situ Hybridization
• Sequencing
• Microarrays
• Laser Capture Microdissection (LCM) and Tissue Arrays
• Mass Spectroscopy
• Other Molecular Platforms

This report provides market estimates and analysis for molecular diagnostics in the following categories:

• Infectious Diseases (including HIV, Hepatitis GC/Chlamydia,Organism ID, MRSA, HAI et al, Mycobacteria, TB Respiratory, Others)
• Blood Screening
• Histology
• Oncology
• Prenatal
• Coagulation
• Tissue Typing
• Inherited Diseases
• Pharmacodiagnostics

The various clinical techniques and trends are discussed from the point of view of their present and potential market impact.

Market analysis in this report covers world markets for in vitro diagnostics, with focus on the developed areas of the globe — North America and Western Europe. However public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases.

As part of its exhaustive coverage of nucleic acid testing, the report includes the following:

• Market Sizes and Forecasts
• Profile and Assessment of Over 140 Key Competitors
• Breakout of Molecular Diagnostic Market by Region (N. America, W. Europe, Asia, ROW)
• Medical and Technological Trends
• Discussion of Globalization of Markets and Diseases
• Information on Reimbursement of New Technologies
• Review of Novel Test Platforms
• Review of New Market Developments, Such as Consumer Genomics and Testing Services
• Discussion of Market Impact of Home Brew Tests
• Discussion of Diagnostic Biomarkers and Genetic Indicators

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Data for the molecular test market are presented in U.S. dollar market size for categories of tests, and for specific analytes where possible. The dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and techniques presented in the report are expected to replace the standard of care in 2007/08, but with healthcare systems’ emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1621/The-World-Market-for-Molecular-Diagnostics.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

This Kalorama Information report – Clinical Nutrition – focuses on three primary segments of essential medical nutrition:

• Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort)
• Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients)
• Parenteral Nutrition

For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall global population. Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets. The market segments provide an overview, description of products on the market, new developments, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

Coverage of Issues and Trends in Clinical Nutrition

There are several issues and trends that are impacting the clinical nutrition market, including:

• Wound Care Applications
• Reimbursement of Nutrition Products
• Food Programs
• Nutrition and Education
• DHA and ANA Additives
• Counterfeit Infant Formulas
• Recalled Infant Formulas
• Acquisition, Mergers and Alliances
• Technology Applications

A Growing Market with Thriving Competition

Competition in the clinical nutrition market is dominated by a handful of companies, ranging from global nutritional manufacturers to leading pharmaceutical companies. The majority of competitive participation is in developed regions such as the United States, Western Europe, and Japan. However, many companies are expanding into less developed regions, intensifying competition in less tapped markets. China, for example, is among the expanding competitive regions as companies continue to break into the growing demand for clinical nutrition in new world markets. Companies highlighted in this study include:

• Abbott Laboratories
• Baxter International
• B. Braun
• Danone
• Fresenius Kabi
• Mead Johnson
• Nestle
• PBM Products
• Wyeth

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 80 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with nutrition company representatives included marketing directors, division managers, and product representatives. All market data pertains to the world market at the manufacturers’ level.

The base year for data was 2008. Historical data was provided for the years 2006 and 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2006-2008, 2008-2013 and 2006-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on demographic trends, new developments, and global expansion.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1626/Clinical-Nutrition-Products-World-Markets-3rd-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions.

This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2008 period and forecasts are provided through 2013.

Since the last edition of this report:

• Vaccine makers are now advertising directly to the public with growing DTC budgets. The report identifies the possible market impact of this new trend.
• The economy has impacted vaccine sales with more people unable to make required out of pocket payments for vaccination.
• New categories of vaccines, such as allergy vaccines, are becoming more prominent, and have been included in our forecasts.
• Several major new products, including Wyeth’s Prevnar 13, are on the horizon. The market impact of new products is discussed.
• Two major mergers – Pfizer/Wyeth and Merck/Schering-Plough, will impact the industry and this is considered in our market analysis.

Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2008. Since Kalorama Information last updated Kalorama Information’s The World Market for Vaccines last year, new products and better than expected profits have transformed the vaccine marketplace. Continued sales of influenza vaccines and cervical cancer vaccines have provided a foundation for growth in the adult market. The competitive dynamics have changed with mergers, and many new products are on the way.

Kalorama Information’s exhaustive research and analysis built from interviews with key decision makers in the market includes the following:

• Review of Products in the Market
• Current World Market Size for Pediatric and Adult Vaccines
• Segmented Revenues and Forecasts to 2013 by Category
• Over 45 Charts and Tables To Make Information Accessible
• Discussion of The Current Economy and Vaccines, Immunization Refusal, Swine/Avian Flu and Other Pandemics, Delivery Sys and other Trends in the Vaccine Market
• Important Vaccines and Immunization Schedules and Statistics
• Profiles of 15 Key Vaccine Companies
• Thorough Review of the Vaccine Pipeline and Possible Impact of New Products

Who are the main players in the vaccine market? What opportunities are available for pharmaceutical companies or investors from this market? What are the potential challenges vaccine competitors must deal with? What will be the impact of the first successful cancer product? What is the significance of at least one major acquisition to affect this industry? These questions and more are tackled in this report.

Current revenues and revenue forecasts to 2013 are included for the following pediatric vaccine categories:

• DTaP & DTP Vaccines
• Hep Vaccines
• HiB Vaccines
• MMR Vaccines
• Combination Vaccines
• Pneumococcal Vaccines
• Polio Vaccines
• Varicella Vaccines
• Other Pediatric Vaccines

As well as Revenues and Forecasts to 2012 for the following adult vaccine categories:

• Influenza Vaccines
• Hepatitis Vaccines
• Pneumococcal Vaccines
• Travel, DT and other Adult Vaccines
• Cervical Cancer

This is a rapidly changing marketplace and knowledge of the R&D pipeline is essential to truly understand what is happening in vaccines. Vaccines in development are discussed in this report, including vaccines for the following conditions:

• Enterotoxigenic Escherichia coli
• Parainfluenza Virus Type 3
• Pneumococcal Vaccines
• Respiratory Syncytial Virus<
• Cancers
• Cholera
• HIV/AIDS
• Helicobacter Pylori
• Malaria
• Rabies
• Tuberculosis
• West Nile Virus

This Kalorama Information report was created with a primary research effort. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1645/Vaccines-2009-World-Market-Analysis-Key-Players-and-Critical-Trends-in-a-Fast-Changing-Industry.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

As Kalorama Information’s lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality have arrived. But is healthcare ready?

Kalorama believes that the drive for wellness and the attention surrounding healthcare reform will focus attention on rapid diagnostics. However, according to Shara Rosen, RT, M.B.A., there are many challenges which must be overcome for point of care solutions to be fully utilized, and those companies willing to pivot strategies and best adjust to tomorrow’s healthcare marketplace may be rewarded.

This report, Point of Care Diagnostics 2010: Rapid Testing at a Crossroads represents the most current analysis of the role POC Diagnostics in today’s in vitro industry. Other reports have looked at products, companies and revenue numbers, as this report does. But in her analysis Shara Rosen takes a bold look into the markets, technologies, and trends in decentralized testing with a special focus on the economics of rapid test use in critical care and emergency medicine. The report includes:

• Markets for POC Diagnostics (Diabetes, Cardiac markers, Clinical Chemistry/Critical Care, Hematology, Coagulation, Drugs of Abuse/Therapeutic Drug Monitoring, Infectious Diseases, Pharmacodiagnostics, Sepsis, Oncology, Women’s health / Pregnancy/Fertility)
• By Venue Revenue Estimates for Hospital POC, Physician POC and Other Venue
• Review of Products in the Market
• Forecasts to 2013
• Markets and Forecasts for Self-Testing (OTC)
• The role of EMR in the Point of Care Market
• Possible Effects of Healthcare Reform
• POLs, Home Monitoring, Alternate Samples and Other Trends
• Successful Strategies of POC Companies
• Profiles of Over 100 Companies Competing in this Market

There are many factors in the growth of POC testing- increasing numbers of diagnosed diabetics, people with cardiovascular disease, and other chronic conditions. It is also expected to play a role in a trend in health care to evaluate provider organizations for quality in care delivery. While this quality imperative is most apparent in pay-for-performance systems, it also provides a framework by which public funds can be used more rationally. This is an especially relevant technology given the U.S. healthcare reform efforts.

All countries are feeling the brunt of aging populations and an increased burden of chronic disease management. Employers and insurance companies are interested in improving the health of customers, and there are some innovative tactics developing in this area. The report is conservative in its predictions and offers a calculated look into the future, based on events currently taking place.

The report offers a quantitative assessment of specific markets in US dollars for 2008 and forecasted out to 2013. These data are provided in order to set the status quo of tests and technologies. However the report concentrates on how these will impact the economics of healthcare over the near term and longer when possible.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1660/Point-of-Care-Diagnostics-2010-and-Beyond-Rapid-Testing-at-a-Crossroads.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? This Kalorama Information report What’s Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched, including the following target areas:

• Addiction
• Allergy
• Alzheimer’s Disease
• Anthrax
• Asthma
• Campylobacter Infection
• Chlamydia
• Croup
• Dengue Fever
• Diabetes
• Ebola
• Epstein-Barr Virus
• Enterotoxigenic Escherichia coli
• Helicobacter Pylori
• Hepatitis
• Herpesvirus
• Hookworm
• Hypertension
• HIV/AIDS
• Leishmaniasis
• Malaria
• MRSA Infection
• Multiple Sclerosis
• Obesity
• Parainfluenza Virus Type 3
• Parkinson’s Disease
• Plague
• Respiratory Syncytial Virus
• Ross River Virus
• Shigellosis
• Smoking
• Stroke
• Tuberculosis
• West Nile Virus

Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Alison Sahoo has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

• Acambis plc
• ACE BioSciences
• AFFiRiS
• ALK-Abello A/S
• Allergy Therapeutics
• Bavarian Nordic A/S
• Baxter Healthcare
• Celldex Therapeutics
• Crucell
• Cytos Biotechnology
• GlaxoSmithKline
• Hawaii Biotech
• Intercell
• Medimmune
• Merck & Co. Inc
• Mymetics
• Nabi Biopharmaceuticals
• Novartis
• Opexa Therapeutics
• Paladin Labs
• Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2020. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1594/What-s-Next-in-Vaccines-HIV-Malaria-Rabies-MRSA-and-30-Other-Vaccine-Targets-in-the-2010-2020-Pipeline.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com